Biological signaling networks such as those associated with RTKs, WNT, TGbeta, and ER are of critical importance for the survival and proliferation of many human carcinomas. We will create a logical model of cellular networks that will be used to understand and explore these complex signaling networks at a systems biology level in human breast cancer. Our model will be constructed using the Pathway Logic system, which is founded on the computational science of formal methods. Pathway Logic allows a rich set of logical operators to define relationships between and among the components of a complex biological system. A Pathway Logic model has compelling advantages for understanding complex biological processes such as signal transduction and metabolism at a global level. In particular, it provides a mechanism for organizing diverse information concerning biological and biochemical states and processes; its structure naturally represents biological and biochemical change; it is automatically created on demand depending on user specified conditions; and it can be easily modified to accommodate new information, respond to logical queries, and formulate hypotheses about the function of complex networks. Our high throughput experimental approach to the construction and validation of a Pathway Logic model for breast cancer (described in Projects 2-3) involves using a large panel of characterized human breast cancer cell lines [o capture molecular and phenotypic responses to targeted therapeutics. Thus, our model must represent unique states of each cell line, rather than an overall state arbitrarily designated as representative of human breast cancer. Further, it must provide a computational mechanism that enable users to interpret experimental results in a format that can be used to build as well as modify the model in response to new findings. Finally, the model must be capable of generating statements or hypotheses that can be experimentally verified in both automatic and interactive ways. The central goal of this project is to construct a comprehensive Pathway Logic model of oncogemc signaling pathways in human breast cancer with emphasis on the Raf-MEK-ERK module using Pathway Logic, and to provide the necessary infrastructure for interacting with it. Achieving this goal will allow Projects 2-3 of the Program to integrate their findings with one another, and allow us to test and define relationships between specific signaling pathways and their sensitivity to therapeutic intervention. To achieve this goal we will:
Aim 1. Develop an expanded Pathway Logic rnodel of cellular signaling networks related to breast cancer. We will systematically develop a large Pathway Logic model of RTKs, WNT, TGFbeta, and ER signaling networks suitable for studying signaling processes in human breast cancer, initially, all established biological interactions and outputs implicated in normal and oncogenic signaling through this network will be curated from public knowledge bases, including both qualitative (logical) and quantitative behaviors. As the model is developed, it will be verified to ensure that correct or expected behaviors are predicted or maintained. The model will be systematically refined by incorporating the results from Projects 2-3. The mature model will inctude each cell line as a distinct part, allowing the specification of unique values and properties for each cell line.
Aim 2. Extend Pathway Logic to increase its functionality and utility. The current Pathway Logic system must be adapted and linked to the experimental plans that will be performed in Project 2-3. To accomplish this, we will (a) build tools too ease model construction by facilitating input; (b) create a comprehensive database of experimental facts relevant for defined experimental states of each cell line (Projects 2-3); (c) develop a system to allow users to investigate effects of perturbing or changing the mode] or network at points of potential therapeutic intervention, providing a foundation for translationally relevant hypotheses; (d) build an automated system to create prototypical model queries that can indicate undefined values or parameters within the model (experimentally determined in Projects 2-3); (e) develop computational strategies to estimate unknown cell state values; and (f) include computational mechanisms for including dynamic processes within the Pathway Logic approach.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA112970-05
Application #
7681594
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-09-30
Budget End
2009-09-29
Support Year
5
Fiscal Year
2008
Total Cost
$489,599
Indirect Cost
Name
Lawrence Berkeley National Laboratory
Department
Type
DUNS #
078576738
City
Berkeley
State
CA
Country
United States
Zip Code
94720
Risom, Tyler; Langer, Ellen M; Chapman, Margaret P et al. (2018) Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat Commun 9:3815
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Xu, Xiaowei; De Angelis, Carmine; Burke, Kathleen A et al. (2017) HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res 23:5123-5134
Hill, Steven M; Nesser, Nicole K; Johnson-Camacho, Katie et al. (2017) Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling. Cell Syst 4:73-83.e10
Seviour, E G; Sehgal, V; Mishra, D et al. (2017) Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. Oncogene 36:1339-1350
Riesco, Adrián; Santos-Buitrago, Beatriz; De Las Rivas, Javier et al. (2017) Epidermal Growth Factor Signaling towards Proliferation: Modeling and Logic Inference Using Forward and Backward Search. Biomed Res Int 2017:1809513
Hassan, Saima; Esch, Amanda; Liby, Tiera et al. (2017) Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer. Mol Cancer Ther 16:2892-2901
Sears, Rosalie; Gray, Joe W (2017) Epigenomic Inactivation of RasGAPs Activates RAS Signaling in a Subset of Luminal B Breast Cancers. Cancer Discov 7:131-133
Gendelman, Rina; Xing, Heming; Mirzoeva, Olga K et al. (2017) Bayesian Network Inference Modeling Identifies TRIB1 as a Novel Regulator of Cell-Cycle Progression and Survival in Cancer Cells. Cancer Res 77:1575-1585
Hafner, Marc; Heiser, Laura M; Williams, Elizabeth H et al. (2017) Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics. Sci Data 4:170166

Showing the most recent 10 out of 193 publications